HIMS241220P24000
- 0.15
- -0.07-31.82%
Hims & Hers Health Newsroom
Morgan Stanley Initiates Hims & Hers Health(HIMS.US) With Buy Rating, Announces Target Price $42
Hims & Hers Health Initiated at Overweight by Morgan Stanley
Hims & Hers Health Analyst Ratings
HIMS Stock Surges 43% in a Month: Will the Uptrend Continue Further?
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), Zymeworks (ZYME) and Axsome Therapeutics (AXSM)
"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
Truist Financial Gives a Hold Rating to Hims & Hers Health (HIMS)
Hims & Hers Health Insider Sold Shares Worth $2,653,129, According to a Recent SEC Filing
Josh Brown Unveils The 'Degen Dow,' A Basket Of 30 Retail Darlings Spanning All 'Major Degen Food Groups'
Unusual Options Activity: CRDO, HIMS and Others Attract Market Bets, CRDO V/OI Ratio Reaches 105.2
EST Dec 12th Afternoon Delivery - In the last two hours of trading, 7 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $18
Challenging Outlook for Hims & Hers Health Amid DTC Model Disruption and Profit Margin Concerns
'Eli Lilly to Sell Zepbound Through Telehealth Company Ro' - Barron's
Hims & Hers Health Unusual Options Activity
Hims & Hers Health, Inc. Falls 7% as Ro Says It Is Working With Eli Lilly to Streamline Access to Zepbound
Ro Partners With Eli Lilly to Enhance Obesity Treatment Access; Hims & Hers Health Shares Fall
Hims & Hers Health Options Spot-On: On December 10th, 88,818 Contracts Were Traded, With 573.71K Open Interest
On December 10th ET, $Hims & Hers Health(HIMS.US)$ had active options trading, with a total trading volume of 88,818 options for the day, of which put options accounted for 47.77% of the total
CCORF Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $38
Hims & Hers Named to Inc.'s 2024 Best in Business List in Health Products Category